Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumors
We utilized the K14-Cre Brca1<sup>f/f</sup>Tp53<sup>f/f</sup> mouse model to investigate whether a pulse of PARP inhibitor (PARPi) ± an AKT inhibitor (AKTi) can prevent Brca1-related breast cancer. PARPi alone did not intercept or prevent tumor development. PARPi+AKTi intercepted tumors but did not prevent new tumors. These data confirm the efficacy of a PARPi and an inhibitor of PI3K signaling in treating BRCA1/2-related tumors, but this combination is not sufficient to prevent carcinogenesis.
Authors
- Barbara Sardella
- G Wulf
- Zhaoji Liu
- E Aronson
- Xiaohui Li
- Yujing J. Heng
- Lin Wang
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1038/s41523-026-00892-6
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- National Cancer Institute